Ocular Therapeutix share price logo

Ocular Therapeutix

NASDAQ: OCUL

Mid Cap

$9.99

-0.15

(-1.48%)

as on

Ocular Therapeutix Stock Performance

as on September 19, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $9.89
    $10.26
    downward going graph

    1.00%

    Downside

    2.70%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $6.23
    $16.44
    downward going graph

    37.64%

    Downside

    64.56%

    Upside

    downward going graph

Ocular Therapeutix share price movements today

Previous Close
$10.14
Open
$10.15
Volume
1.8M
Market Cap
$2.2B
Day's Low - High
$9.89 - $10.26
52 Week Low - High
$6.23 - $16.44

Ocular Therapeutix Historical Returns

1 Month Return
-13.55 %
3 Month Return
+ 7.53 %
1 Year Return
-16.2 %
3 Year Return
+ 198.24 %
5 Year Return
-3.89 %

Ocular Therapeutix Stock Fundamentals & Key Indicators

Check Ocular Therapeutix market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.2B

EPS (TTM)

-1.42

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.14

Industry PE ratio

-13.55

PEG Ratio

0.6290765839537554

EBITDA

-284.6M

Revenue (TTM)

52.1M

Profit Margin

87.11%

Return On Equity TTM

-59.87%

Ocular Therapeutix Stock Valuation

Track how Ocular Therapeutix P/E has moved over time to understand its valuation trends.

Ocular Therapeutix in the last 5 years

  • Overview

  • Trends

Lowest (-81.25x)

December 31, 2021

Industry (-13.55x)

December 31, 2025

Today (-8.55x)

December 31, 2025

Highest (-3.04x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -8.55x

Ocular Therapeutix vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Ocular Therapeutix with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Ocular Therapeutix image
Ocular Therapeutix
BUY$2.2B-3.89%-7.1487.11%0.00%
Moderna image
Moderna
BUY$63.1B-63.24%-19.81-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$130.1B174.21%29.8186.04%0.00%
Regeneron image
Regeneron
BUY$79.7B21.1%18.4884.86%0.48%

Stock Returns calculator for Ocular Therapeutix Stock including INR - Dollar returns

The Ocular Therapeutix stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ocular Therapeutix investment value today

Current value as on today

₹89,853

Returns

-₹10,147

(-10.15%)

Returns from Ocular Therapeutix Stock

-₹17,438 (-17.44%)

Dollar Impact

₹7,291 (+7.29%)

Analyst Recommendation on Ocular Therapeutix Stock

Based on 9 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 9 analysts, 100% of analysts recommend a 'BUY' rating for Ocular Therapeutix. Average target price of $27.09

Ocular Therapeutix Share Price Target

Get share price movements and forecasts by analysts on Ocular Therapeutix.

What analysts predicted

63.12%UPSIDE

Target Price

$27.09

Current Price

$9.99

Analyzed by

9 Analysts

Target

$27.09

Ocular Therapeutix target price $27.09, a slight upside of 63.12% compared to current price of $9.99. According to 9 analysts rating.

Indian Investors' Interest in Ocular Therapeutix Stock

Search interest for Ocular Therapeutix Stock has increased by 70% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:70% versus previous 30 day period

Ocular Therapeutix Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
14
16
15
17
10
13
14
13
10
13
Gross Profit
13
14
13
15
9
11
12
11
9
11
Operating Income
-31
-43
-45
-50
-63
-67
-68
-69
-93
-82
EBITDA
-59
-39
-32
-44
-60
-63
-65
-60
-84
-74
Interest Expense
4
3
3
3
2
3
3
2
2
2
Depreciation
0
0
0
0
0
1
1
1
1
1
Income Before Tax
-64
-43
-36
-48
-64
-67
-69
-64
-88
-78
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-64
-43
-36
-48
-64
-67
-69
-64
-88
-78
Net Profit Margin
91.02%
90.82%
89.88%
92.80%
88.20%
85.56%
87.80%
87.97%
87.68%
85.08%

Ocular Therapeutix Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
1
4
17
43
51
58
63
51
Gross Profit
1
1
1
15
39
46
53
58
45
Operating Income
-61
-59
-85
-62
-78
-78
-82
-171
-270
EBITDA
-59
-55
-77
-146
2
-61
-66
-176
-249
Interest Expense
1
1
6
6
6
7
11
13
11
Depreciation
1
2
2
2
2
2
2
3
4
Income Before Tax
-63
-59
-86
-155
-6
-71
-80
-193
-265
Income Tax Expense
0
-2
-
-
-
-
-
-
-
Net Income
-63
-57
-86
-155
-6
-71
-80
-193
-265
Net Profit Margin
76.24%
76.63%
45.00%
88.03%
89.88%
91.18%
90.96%
91.17%
87.31%

Ocular Therapeutix Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-64
-43
-36
-48
-64
-67
-69
-64
-88
-78
Operating Cash Flow
-33
-24
-36
-39
-44
-55
-50
-54
-65
-67
Investing Cash Flow
0
0
0
0
-1
-1
-5
-2
-4
-3
Financing Cash Flow
321
2
4
4
4
97
10
449
0
2
Change in Cash
287
-23
-32
-35
-42
41
-46
392
-70
-68

Ocular Therapeutix Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-63
-59
-86
-155
-6
-71
-80
-193
-265
Operating Cash Flow
-50
-49
-77
-53
-65
-59
-70
-134
-204
Investing Cash Flow
27
-1
-2
0
-1
-3
-6
-1
-11
Financing Cash Flow
32
68
75
228
2
1
169
332
561
Change in Cash
8
17
-4
173
-63
-61
93
196
344

Mutual Funds that own Ocular Therapeutix Stock

Check out the Mutual Funds with significant holdings in Ocular Therapeutix.

Funds
Holdings
Shares Held
Fidelity Mt. Vernon Street Trust
6.636261%
14574284
VANGUARD INDEX FUNDS
3.870215%
8499607
Fidelity Select Portfolios
1.188553%
2610252
Fidelity Salem Street Trust
0.924061%
2029385
Fidelity Concord Street Trust
0.790979%
1737116
See all

Global Institutional Holdings in Ocular Therapeutix

Funds
Holdings
Vanguard
4.8%
iShares
4.06%
SPDR
0.87%
Invesco
0.77%
Dimensional
0.76%
See all

Ocular Therapeutix News & Key Events

  • img

    Today's Timeline - 01 September

    Tue, 04:30 PM

    -

    Ocular Therapeutix announces participation in several investor and scientific conferences scheduled for September and October 2026.

    Tue, 09:33 PM

    -

    Bank of America maintains Buy rating on Ocular stock, citing strong potential for Axpaxli and positive Phase 3 data.

Insights on Ocular Therapeutix

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -88.61M → -78.76M (in $), with an average increase of 12.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, OCUL has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 10.78M → 13.47M (in $), with an average increase of 20.0% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, OCUL stock has moved up by 193.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 510.3% return, outperforming this stock by 527.7%

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
OrganisationOcular Therapeutix
Headquarters24 Crosby Drive, Bedford, MA, 01730, US
IndustryBiotechnology
CEOPravin U. Dugel
E-voting on sharesClick here to vote

Key Management of Ocular Therapeutix

Name

Title

Mr. William S. Slattery Jr.

Vice President of Investor Relations

Mr. Donald Notman Jr.

Chief Operating Officer (Leave of Absence)

Mr. Sanjay Nayak MBBS, Ph.D.

Chief Strategy Officer

Mr. Jason Robins

CFO & Principal Accounting Officer

Dr. Peter K. Jarrett Ph.D.

Chief Technical Officer

Dr. Jeffrey S. Heier M.D.

Chief Scientific Officer

Dr. Pravin U. Dugel M.D.

Executive Chairman, President & CEO

Mr. Steve Meyers

Chief Commercial Officer

Dr. Nadia K. Waheed M.D., M.P.H.

Chief Medical Officer

Mr. Todd D.C. Anderman J.D.

Chief Legal Officer & Corporate Secretary

FAQs

What is Ocular Therapeutix share price today?

Ocular Therapeutix share price today is $9.99 as on at the close of the market. Ocular Therapeutix share today touched a day high of $10.26 and a low of $9.89.

What is the 52 week high and 52 week low for Ocular Therapeutix share?

Ocular Therapeutix share touched a 52 week high of $16.44 on and a 52 week low of $6.23 on . Ocular Therapeutix stock price today i.e. is closed at $9.99,which is 39.23% down from its 52 week high and 60.35% up from its 52 week low.

What is Ocular Therapeutix's market capitalisation today?

Ocular Therapeutix market capitalisation is $0.00T as on .

How to invest in Ocular Therapeutix Stock (OCUL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Ocular Therapeutix on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ocular Therapeutix Shares that will get you 0.1502 shares as per Ocular Therapeutix share price of $9.99 per share as on September 19, 2026 at 8:46 am IST.

What is the minimum amount required to buy Ocular Therapeutix Stock (OCUL) from India?

Indian investors can start investing in Ocular Therapeutix (OCUL) shares with as little as ₹95.88 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.80 in Ocular Therapeutix stock (as per the Rupee-Dollar exchange rate as on ). Based on Ocular Therapeutix share’s latest price of $9.99 as on September 19, 2026 at 8:46 am IST, you will get 1.0010 shares of Ocular Therapeutix. Learn more about fractional shares .

What are the returns that Ocular Therapeutix has given to Indian investors in the last 5 years?

Ocular Therapeutix stock has given -3.89% share price returns and 30.29% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?